EUVIMEDEUVIMED entdecken
Editorial

Editorial: Retuning the Adolescent Brain: Esketamine and Rapid Structural Change in the rACC

Yunjia Liu, Qiang Wang

Journal of the American Academy of Child & Adolescent Psychiatry · 2026-11 · 65 (11) · 1344-1346

DOI: 10.1016/j.jaac.2026.03.007 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of the American Academy of Child & Adolescent Psychiatry, 2026-11. Verfasst von Yunjia Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health Center & National Center of Mental Disorders, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Behavioral Health Ser…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Ketamine, Brain, Antidepressive Agents. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Chengdu Municipal Science and Technology Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adolescent major depressive disorder (MDD) is a leading cause of disability worldwide and a major, modifiable risk factor for suicide, which remains the second leading cause of death in this age group.1 For 30% to 50% of patients who fail to achieve remission despite multiple treatment steps, the clinical and psychosocial consequences are substantial.2 Although selective serotonin-reuptake inhibitors are widely used as first-line treatments, their therapeutic effects typically require several weeks to emerge, and a substantial proportion of adolescents do not respond to an initial antidepressant trial. Together, the delayed efficacy and incomplete response contribute to a critical treatment gap during which vulnerable youth remain at elevated risk. These limitations have driven growing interest in rapid-acting interventions such as the N-methyl-D-aspartate (NMDA) receptor antagonist esketamine. Multiple pieces of evidence suggest that esketamine can produce faster symptom relief than conventional antidepressants,2 including efficacy as a monotherapy in treatment-resistant depression3; however, its neural mechanisms remain incompletely understood. A clearer understanding of how esketamine acts on the developing brain is necessary to guide clinical use and to inform more targeted prevention strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderKetamineBrainAntidepressive AgentsHumansAdolescent

Substanzen

KetamineEsketamineAntidepressive Agents

Autor:innen und Institutionen

  • Mental Health Center & National Center of Mental Disorders, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Behavioral Health Services and Psychiatry Research, Henry Ford Health, Detroit, Michigan.
  • Mental Health Center & National Center of Mental Disorders, West China Hospital of Sichuan University, Chengdu, Sichuan, China. Electronic address: wangqiang130@scu.edu.cn.

Förderung

  • Chengdu Municipal Science and Technology Program
  • National Natural Science Foundation of China

Zitieren

APA

Liu, Y., & Wang, Q. (2026). Editorial: Retuning the Adolescent Brain: Esketamine and Rapid Structural Change in the rACC. Journal of the American Academy of Child & Adolescent Psychiatry, 65(11), 1344-1346. https://doi.org/10.1016/j.jaac.2026.03.007

Vancouver

Liu Y, Wang Q. Editorial: Retuning the Adolescent Brain: Esketamine and Rapid Structural Change in the rACC. Journal of the American Academy of Child & Adolescent Psychiatry. 2026;65(11):1344-1346. doi:10.1016/j.jaac.2026.03.007

BibTeX
@article{Liu2026,
  author = {Liu, Yunjia and Wang, Qiang},
  title = {Editorial: Retuning the Adolescent Brain: Esketamine and Rapid Structural Change in the rACC},
  journal = {Journal of the American Academy of Child & Adolescent Psychiatry},
  year = {2026},
  volume = {65},
  number = {11},
  pages = {1344--1346},
  doi = {10.1016/j.jaac.2026.03.007}
}
Kostenlos starten →